NGT HealthCare II, an impact fund from Nazareth focusing on health technologies, has launched a new fund with commitments of about $92 million (NIS 300 million) for investments in its portfolio companies.
The funds are intended for investments in breakthrough technologies originating, among others, from academic and medical commercialization arms. Special attention will be given to promoting entrepreneurship from the Arab society.
The capital funds will be allocated towards investments in breakthrough technologies emerging from academic, medical, and commercial verticals with a heavy emphasis on promoting entrepreneurship opportunities for individuals from Arab communities.
In addition, NGT HealthCare II will leverage grants totaling around $30 million as a result of winning the Israel Innovation Authority’s incubator tender.
These funds will allow NGT HealthCare II to supply early-stage investments and follow-up investments in approximately 25 early-phase startups and 16 “year zero” projects (academic projects considered as pre-incubator) specializing in biotechnology, bioconvergence, and the advancement of medical devices.
Companies joining the Fund’s portfolio will be granted access to the Fund’s Nazareth offices and laboratories as well as its professional network to receive support regarding in-depth market analysis, pre-clinical and clinical trials, and brokering relations with strategic players for capital investment.
The Technion – Israel Institute of Technology’s commercialization arm, T3, as well as the technology transfer company of Hadassah Jerusalem, Hadassit, and many others have joined as strategic partners in the Fund alongside existing partners Arkin Holdings and Jacobs Investment Company LLC.
Established in 2021, the mission of NGT Healthcare II is to invest in companies operating in the fields of biotechnology, bioconvergence, and medical device engineering. NGT’s first fund was established in 2013 with the Innovation Authority franchise to operate a technological incubator in Nazareth, which aided in developing 23 new medical companies.
“We will continue to build innovative life science companies, commercialize technologies from universities and hospitals, and encourage entrepreneurs from the Arab society,” said Zohar Gendler, Managing Partner and CEO of NGT HealthCare II. “Our exceptional partners, and the extensive collaborations we have built with academic and health institutes in Israel and abroad, provide us with high accessibility to new projects that are now gaining high leverage from the Innovation Authority together with our funds. NGT HealthCare II and its partners will also support these companies later, after the initial investment period.”
